Brief: Kiora Pharmaceuticals Reports Kio-101 Safe And Tolerable Topline Data Supports Advancing Kio-101 To Phase 2 Study In Patients With Dry Eye Disease
14/12/2021 12:36
Dec 14 (Reuters) - Kiora Pharmaceuticals KPRX.O :
* KIORA PHARMACEUTICALS - REPORTS KIO-101 SAFE AND
TOLERABLE;
TOPLINE DATA SUPPORTS ADVANCING KIO-101 TO PHASE 2 STUDY IN
PATIENTS WITH DRY EYE DISEASE
Source text for Eikon: ID:
Further company coverage: KPRX.O
((reuters.briefs@thomsonreuters.com;))
Recent news on Kiora Pharmaceuticals
See all newsKiora Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Kiora Pharmaceuticals, Inc. expected to post a loss of 62 cents a share - Earnings Preview
Brief: Kiora Pharmaceuticals Inc - Enters Securities Purchase Agreement On April 3, 2026 - SEC Filing
Kiora Pharmaceuticals posts 2025 net loss as expenses rise
Brief: Kiora Pharmaceuticals Files For Mixed Shelf Offering Of Up To $100 Million- SEC Filing